Strong sales growth contrasts with widening losses, keeping margins, debt, and execution under the spotlight
New York, United States, 27 February 2026 – Elanco Animal Health closed FY 2025 with a mixed financial picture that continues to divide investor opinion. While revenue showed steady improvement, profitability remained elusive, underscoring the challenges the company faces as it tries to balance growth, margins, and long-term expectations.
In the fourth quarter of FY 2025, Elanco reported revenue of US$1.14 billion, up from US$1.02 billion in the same quarter last year. Over the trailing twelve months, revenue reached approximately US$4.7 billion. These figures confirm that demand for the company’s animal health products remains solid across its markets.
However, earnings tell a more complicated story. Elanco posted a basic loss per share of US$0.56 in Q4 2025, compared with periods earlier in the year when profitability briefly returned. Across FY 2025, earnings swung sharply, moving from a US$67 million profit in Q1 to a US$276 million loss in Q4. On a trailing twelve-month basis, the company ended the year with a total net loss of about US$232 million.
For investors, this uneven performance keeps margins firmly in focus. Supporters of the company argue that earnings can rebound over the next few years, pointing to forecasts that suggest profits could return by around 2028. Those projections assume a clear shift from today’s losses to positive margins, a transition that will require tighter cost control, operational efficiency, and consistent execution.
At the same time, revenue growth appears steady but slower than the broader market. Elanco’s trailing twelve-month revenue increased from roughly US$4.4 billion to US$4.7 billion over recent periods, aligning with mid single-digit growth assumptions. Analysts comparing this pace with the wider US market, which is often cited as growing at a faster rate, see a company that is expanding, but not aggressively outperforming its peers.
Another layer of complexity comes from valuation. Despite ongoing losses, Elanco shares trade near US$26.84, while discounted cash flow estimates place fair value closer to US$36.95. The company’s price-to-sales ratio also sits below both industry and peer averages. This suggests the market has already priced in a degree of caution around profitability, debt levels, and future growth.
Skeptics remain focused on leverage and interest costs, which add pressure at a time when earnings are negative. Supporters counter that the valuation discount provides room for upside if management can stabilize margins and return to profitability over the medium term.
For now, Elanco sits at an intersection of optimism and concern. Revenue momentum shows the business has scale and demand, but choppy earnings highlight how much work remains before those sales translate into consistent profits. Investors watching the stock will be looking closely at whether future quarters show progress toward narrowing losses and strengthening margins.
Further analysis and community perspectives on Elanco’s outlook, risks, and valuation are available through platforms such as Simply Wall St, where investors can track how expectations evolve alongside new financial results.